Current Report Filing (8-k)
June 10 2021 - 9:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 10, 2021
AIKIDO
PHARMA INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-05576
|
|
52-0849320
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
One
Rockefeller Plaza, 11th Floor, New York, NY
|
|
10020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code: (703) 992-9325
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.0001 par value
|
|
AIKI
|
|
The
Nasdaq Capital Market
|
Item
8.01 Other Events.
On
June 10, 2021, AIkido Pharma Inc., a Delaware corporation (the “Company”), will be presenting the presentation deck attached
hereto as Exhibit 99.1 (the “Presentation”) summarizing the Company’s current drug products at the 2021 LD Micro Invitational
XI Investor Conference.
Item
9.01. Financial Statements and Exhibits
d) Exhibits.
The
exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AIKIDO
PHARMA INC.
|
|
|
|
By:
|
/s/
Anthony Hayes
|
|
Name:
|
Anthony
Hayes
|
|
Title:
|
Chief
Executive Officer
|
Dated:
June 10, 2021
2
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Sep 2023 to Sep 2024